Tempest Therapeutics Stock Forum

$Tempest Therapeutics (TPST.US)$
Tempest Therapeutics’ PPARalpha inhibitor receives FDA orphan designation
is this a good news

$Tempest Therapeutics (TPST.US)$ its ok. i can wait.

$Tempest Therapeutics (TPST.US)$  This is a great stock!  I think it's got a lot of POTENTIAL. I am looking for this to go down at least to the ¢60s maybe ¢70s due to the potential for a reverse split. I do believe it'll be a small one this company does not need to raise that much money and they have approval coming up this next year hopefully. I'm going to try and pick up as many cheap shares as I can. Right now I'm using half of my gains from here in XRP and I made quite a bit thankfully. lol S...

$Tempest Therapeutics (TPST.US)$ who faking price movement

Why Tempest Therapeutics Inc. ( $Tempest Therapeutics (TPST.US)$  ) is a good buy:
1. Innovative Pipeline: TPST is a clinical-stage biotechnology company focused on developing small molecule therapeutics for cancer treatment. Their leading programs, TPST-1495 and TPST-1120, are in Phase 1 trials targeting various tumors.
2. Strategic Partnerships: The company has a collaboration with Roche to advance TPST-1120 in combination with other therapies...

$Tempest Therapeutics (TPST.US)$ Hey good morning guys and gals. I am definitely 100% on board with this I believe it has a lot of potential but but but but. Keep in mind it's got a reverse split coming for 1/2 or 1/15 I sold half to have plenty of ammunition to buy in when it dips. I'm looking for ¢ .70 or under.  I don't see this is a bad thing. NFA Just my two pennies worth.

$Tempest Therapeutics (TPST.US)$ if you would like to gamble on this kind of growth company, you must be well prepared for the dip and loss or holding for the long term. Complaining doesn't help.

$Tempest Therapeutics (TPST.US)$
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...